Key Points
- Vivek Ramaswamy sold 353,745 Roivant shares on December 15 at an average price of $22.05 for $7,800,077.25, leaving him with 34,132,463 shares (a 1.03% reduction) valued at about $752.6 million.
- This transaction is part of a recent streak of insider sales (Dec 11, Dec 12, Nov 14, Nov 17, Nov 13) that together generated more than $105 million in proceeds.
- Roivant trades near its one‑year high ($22.56) with a market cap of about $15.23 billion, and analysts have a consensus "Moderate Buy" with an average target of $24.81 (Goldman Sachs at $33).
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) major shareholder Vivek Ramaswamy sold 353,745 shares of the company's stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $22.05, for a total transaction of $7,800,077.25. Following the completion of the sale, the insider directly owned 34,132,463 shares of the company's stock, valued at $752,620,809.15. The trade was a 1.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Vivek Ramaswamy also recently made the following trade(s):
- On Thursday, December 11th, Vivek Ramaswamy sold 774,142 shares of Roivant Sciences stock. The stock was sold at an average price of $21.64, for a total transaction of $16,752,432.88.
- On Friday, December 12th, Vivek Ramaswamy sold 1,975,858 shares of Roivant Sciences stock. The stock was sold at an average price of $21.96, for a total transaction of $43,389,841.68.
- On Monday, November 17th, Vivek Ramaswamy sold 539,650 shares of Roivant Sciences stock. The stock was sold at an average price of $20.51, for a total transaction of $11,068,221.50.
- On Friday, November 14th, Vivek Ramaswamy sold 1,027,670 shares of Roivant Sciences stock. The stock was sold at an average price of $20.33, for a total transaction of $20,892,531.10.
- On Thursday, November 13th, Vivek Ramaswamy sold 287,283 shares of Roivant Sciences stock. The shares were sold at an average price of $20.81, for a total value of $5,978,359.23.
Roivant Sciences Stock Performance
Shares of NASDAQ:ROIV opened at $21.90 on Tuesday. The company has a market capitalization of $15.23 billion, a PE ratio of -39.11 and a beta of 1.22. The stock has a fifty day moving average of $19.49 and a 200-day moving average of $14.81. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $22.56.
Institutional Trading of Roivant Sciences
A number of institutional investors have recently added to or reduced their stakes in ROIV. Bessemer Group Inc. increased its stake in shares of Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after purchasing an additional 583 shares during the last quarter. Utah Retirement Systems boosted its holdings in Roivant Sciences by 3.0% in the third quarter. Utah Retirement Systems now owns 20,626 shares of the company's stock worth $312,000 after purchasing an additional 600 shares in the last quarter. Xponance Inc. increased its position in Roivant Sciences by 1.9% during the third quarter. Xponance Inc. now owns 46,718 shares of the company's stock worth $707,000 after buying an additional 882 shares during the last quarter. Finally, CWM LLC raised its holdings in Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company's stock valued at $34,000 after buying an additional 920 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on ROIV shares. HC Wainwright upped their target price on Roivant Sciences from $23.00 to $26.00 and gave the company a "buy" rating in a report on Friday. Citigroup boosted their price objective on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, November 11th. Jefferies Financial Group upped their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Thursday, September 18th. JPMorgan Chase & Co. lifted their target price on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an "overweight" rating in a research note on Thursday, September 18th. Finally, The Goldman Sachs Group boosted their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a "buy" rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $24.81.
Check Out Our Latest Research Report on Roivant Sciences
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
